Use the hyperlinks, where available to access additional clinical trial information.
A First-in-human, Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of EMB-06 in Patients With Recurrent or Refractory Multiple Myeloma
Shanghai EpimAb Biotherapeutics Co., Ltd.
This trial has one experimental arm split into two phases. In Phase 1, participants will receive EMB-06 once weekly (intravenously) at different ascending dose levels. In Phase 2, participants will receive EMB-06 once weekly (intravenously) at a dose level (RP2D).